Alza and Theratechnologies combine products:
This article was originally published in Clinica
Alza and Theratechnologies are to develop a new product incorporating Alza's Macroflux transdermal drug delivery technology with Theratechnologies' growth hormone-releasing factor analogue (ThGRF). The Macroflux system incorporates a titanium microprojection array that creates superficial pathways through the skin barrier to allow for the transportation of therapeutic proteins and vaccines, says Theratechnologies, of Saint-Laurent, Quebec. ThGRF is being assessed as a treatment for muscle wasting and for sleep disorders.